Narcolepsy Type 1 Clinical Trial
Official title:
A Long-term Extension Study to Evaluate the Safety and Tolerability of TAK-861 in Participants With Selected Central Hypersomnia Conditions
The main aim is to evaluate the safety and tolerability of TAK-861 on participants with type 1 and type 2 narcolepsy from previous parent studies, TAK-861-2001 (NCT05687903) and TAK-861-2002 (NCT05687916).
The drug being tested in this study is called TAK-861. TAK-861 is being tested to treat people who have narcolepsy type 1 (NT1) and narcolepsy type 2 (NT2). This study will look at the safety of TAK-861 along with improvement in narcolepsy symptoms, including excessive daytime sleepiness (EDS) and number of cataplexy episodes. The study will enroll up to 160 patients from controlled studies conducted with TAK-861. Participants will be assigned to one of the treatment groups according to the dose assigned to them in their parent study. Similarly, participants who were previously on a placebo dose will also be assigned to one of the treatment groups randomly. All participants in the study will receive TAK-861. Participants with NT1 will receive the following dose from the parent study: - TAK-861 Dose 1 - TAK-861 Dose 2 - TAK-861 Dose 3 - TAK-861 Dose 4 Participants with NT2 will receive either TAK-861 Dose 1 or TAK-861 Dose 2 from the parent study. This multi-center trial will be conducted worldwide. The overall time to participate in this study is approximately 108 weeks. Participants will make multiple visits to the clinic (with some visits optionally conducted by home health), and will have a follow up assessment 4 weeks after last dose of study drug. ;
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Not yet recruiting |
NCT05983731 -
A Pilot Observational Study to Assess the Ability of Continuous 'Home' EEG to Accurately Diagnose Narcolepsy and Demonstrate Response to Treatment
|
||
| Suspended |
NCT04419792 -
'A Profile of Physical Performance Variables in an Out-patient Adult Population With Narcolepsy'
|
||
| Completed |
NCT05375890 -
Clinical and Neurophysiological Characteristics of Narcolepsy
|
||
| Not yet recruiting |
NCT06292598 -
Bacterial Translocation and Gut Microbiota in Type 1 Narcolepsy Patients Versus a Control Population
|
||
| Recruiting |
NCT06358950 -
A Study to Evaluate the Safety and Effectiveness of ALKS 2680 in Subjects With Narcolepsy Type 1 (ALKS 2680-201)
|
Phase 2 | |
| Not yet recruiting |
NCT06457945 -
Mind-wandering and Predictive Processes in Narcolepsy: a Putative Mechanism Through Covert REM Intrusions
|
N/A | |
| Not yet recruiting |
NCT06383806 -
Decreasing Nightmares in Adults With Narcolepsy
|
N/A | |
| Not yet recruiting |
NCT05914194 -
A Eight-Week Study of NLS-2 (Mazindol Extended Release) in Participants With Narcolepsy Type 1
|
Phase 3 | |
| Completed |
NCT05687903 -
A Study of TAK-861 in Participants With Narcolepsy Type 1
|
Phase 2 | |
| Recruiting |
NCT05967832 -
Contribution of 7 Tesla MRI of the Hypothalamus in the Diagnosis of Type 1 Narcolepsy
|
N/A | |
| Completed |
NCT05709873 -
Narcolepsy Nightmare Study
|
N/A | |
| Recruiting |
NCT04483310 -
Meditation-Relaxation (MR Therapy) for Sleep Paralysis.
|
N/A | |
| Completed |
NCT04445129 -
Wake and Sleep State Transitions on a Portable Electroencephalogram (EEG) Device in Narcolepsy Type 1 (NT1) and Healthy Participants
|
||
| Completed |
NCT05460052 -
Evaluation of the Effectiveness of a Physical Activity Program on the Severity of Narcolepsy
|
||
| Completed |
NCT05314556 -
Group Psychotherapy in Narcolepsy Type 1
|
N/A | |
| Recruiting |
NCT06336057 -
Mentalizating in Adults Suffering From Narcolepsy Type 1.
|
||
| Recruiting |
NCT06251063 -
Improving Social Relationships for Adolescents With Central Disorders of Hypersomnolence
|
N/A | |
| Completed |
NCT06241911 -
Transcutaneous Auricular Vagus Nerve Stimulation in Patients With Narcolepsy Type 1
|
N/A |